Podofilox
- Atc Codes:D06BB04
- CAS Codes:518-28-5
- PHARMGKB ID:518-28-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Austria: Condylox; Belgium: Wartec; Bulgaria: Condylin; Czech Republic: Wartec; Denmark: Condyline, Wartec; Estonia: Wartec; Finland: Condyline, Wartec; France: Condyline; Germany: Condylox, Wartec; Greece: Podofilox, Wartec; Ireland: Condyline, Warticon; Italy: Condyline; Lithuania: Wartec; Netherlands: Condyline, Wartec; Poland: Condyline, Wartec; Romania: Condyline, Wartec; Slovakia: Wartec; Spain: Wartec; Sweden: Wartec; UK: Warticon.
North America
Canada: Condyline, Wartec; USA: Condylox, Podofilox.
Latin America
Argentina: Podoxín; Brazil: Wartec; Mexico: Wartec.
Drug combinations
Chemistry
Podofilox: C~22~H~22~O~8~. Mw: 414.41. (1) Furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, [5R-(5α,5aβ,8aα,9α)]-; (2) Podophyllotoxin; (3)(5R,5aR,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3′,4′:6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one. CAS-518-28-5 (1989).
Pharmacologic Category
Skin and Mucous Membrane Agents, Miscellaneous; Keratolytic Agent. (ATC-Code: D06BB04).
Mechanism of action
The effect on Human papillomavirus (HPV) warts may be related to interference with microtubular function of keratinocytes contained in warts and local vascular structures and may also be related to local immunomodulating effects. May have anti-inflammatory activity related to decrease in tumor necrosis factor receptors.
Therapeutic use
Treatment of external genital warts.
Pregnancy and lactiation implications
Unknown whether topically applied podofilox distributed into human milk. Use with caution during pregnancy or lactation.
Unlabeled use
Contraindications
Known hypersensitivity or intolerance to podofilox or any ingredient in the formulation.
Warnings and precautions
HIV-infected individuals may not respond as well and may have more frequent recurrences of genital HPV warts after treatment compared with immunocompetent individuals. Women with genital HPV warts should be advised to undergo regular Papanicolaou tests as recommended for women without genital HPV warts.